Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 243 results:
Author Title [ Type] Year Filters: Author is Karagiannis, Asterios [Clear All Filters]
Should we expand the concept of coronary heart disease equivalents?.
Curr Opin Cardiol. 29(4), 389-95.
(2014). Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial..
J Hepatol. 57(2), 476.
(2012). Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice..
Cardiovasc Hematol Disord Drug Targets. 18(2), 139-146.
(2018). Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism..
Expert Opin Pharmacother. 9(4), 509-15.
(2008). Stage of chronic kidney disease and severity of coronary heart disease manifestation..
Expert Opin Pharmacother. 13(4), 457-60.
(2012). Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?.
Curr Med Res Opin. 26(4), 839-42.
(2010). Statin-fibrate combination for mixed dyslipidaemia: a limited option?.
Curr Med Res Opin. 26(9), 2137-40.
(2010). Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients..
Open Cardiovasc Med J. 1, 8-14.
(2007). Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention..
Curr Vasc Pharmacol. 7(3), 264-6.
(2009). Statins and heart failure..
J Am Coll Cardiol. 55(15), 1644-5; author reply 1646.
(2010). Statins and nonalcoholic fatty liver disease: a bright future?.
Expert Opin Investig Drugs. 22(9), 1089-93.
(2013). Statins and non-alcoholic steatohepatitis..
J Hepatol. 64(1), 241-2.
(2016). Statins and regression of coronary atherosclerosis..
JAMA. 297(20), 2197; author reply 2197.
(2007). Statins and renal function. Is the compound and dose making a difference?.
Nephrol Dial Transplant. 22(3), 963-4; author reply 964.
(2007). Statins and Type 2 Diabetes Mellitus: An Update After 1 Year..
Curr Pharm Des. 22(18), 2723-5.
(2016). Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?.
Expert Opin Pharmacother. 16(10), 1449-61.
(2015). Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures..
Curr Drug Targets. 8(8), 942-51.
(2007). Statins for the prevention of first or recurrent stroke..
Curr Vasc Pharmacol. 6(2), 124-33.
(2008). Subclinical Cushing's syndrome and cardiovascular disease..
Lancet Diabetes Endocrinol. 2(5), 361.
(2014). Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?.
J Hypertens. 36(3), 701.
(2018). Targeted analysis of three hormonal systems identifies molecules associated with the presence and severity of NAFLD..
J Clin Endocrinol Metab.
(2019). Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?.
Curr Vasc Pharmacol. 14(1), 88-97.
(2016). Targeting vascular risk in patients with metabolic syndrome but without diabetes..
Metabolism. 54(8), 1065-74.
(2005). Therapeutic options for statin-intolerant patients..
Curr Med Res Opin. 28(3), 345-9.
(2012). Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?.
Open Cardiovasc Med J. 6, 28-32.
(2012).